BOC Sciences provides a variety of strategies for antibody-drug conjugate (ADC) to customers around the world. BOC Sciences has the most advanced equipment, unique R&D expertise, and can provide personalized antibody coupling services for different customers in a short time. In the process of development and optimization, we will monitor our products according to strict quality control standards to ensure that our customers receive first-class services and products.
In recent years, the development of ADCs has been launched around the world. This is a new kind of biotechnological drug for treatment. It is a kind of powerful anticancer drug targeting cancer cells and considered to be an important means of disease treatment in the future. The complex structure of the ADC and its high degree of heterogeneity pose great challenges for its structural characterization and characterization. Among them, the determination of the drug-to-antibody ratio (DAR), the drug coupling site, and the coupling ratio of the site are quite complicated and difficult. BOC Sciences's solutions will help you solve these problems and challenges.
Depending on the reaction site, the conjugation strategies can be divided into non-specific conjugation by native residues, site-specific conjugation by genetic engineering sites and UV cross-linking. Non-specific conjugation techniques include: lysine conjugation, cysteine conjugation, which has the advantage that this method is classical and mature, without the introduction of non-natural amino acids. Site-specific conjugation can increase the site specificity of ADC conjugation by altering the amino acid sequence to introduce a reactive handle, including enzymatic modified antibodies and the like. Enzymatic modified antibodies enable enzyme-chemical two-step efficient site-directed conjugation, and certain enzymes recognize specific amino acid tags. In addition, unnatural amino acids conjugation can introduce special groups to facilitate efficient specific conjugation reactions.
At present, ADC is considered to be a very important and promising anti-tumor drug. Four conjugates have been approved by regulatory agencies for the treatment of cancer patients. According to the characteristics of the antibody and the specific requirements of the customer, BOC Sciences can choose the most appropriate coupling strategy for the ADC you are interested in.